Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 5
1986 5
1987 9
1988 4
1989 1
1990 3
1991 2
1992 5
1993 6
1994 9
1995 6
1996 13
1997 20
1998 14
1999 16
2000 27
2001 31
2002 46
2003 38
2004 65
2005 67
2006 81
2007 100
2008 96
2009 110
2010 110
2011 112
2012 107
2013 97
2014 95
2015 101
2016 81
2017 57
2018 70
2019 68
2020 63
2021 65
2022 53
2023 44
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

1,647 results

Results by year

Filters applied: . Clear all
Page 1
Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial.
Hoge EA, Bui E, Mete M, Dutton MA, Baker AW, Simon NM. Hoge EA, et al. JAMA Psychiatry. 2023 Jan 1;80(1):13-21. doi: 10.1001/jamapsychiatry.2022.3679. JAMA Psychiatry. 2023. PMID: 36350591 Free PMC article. Clinical Trial.
Secondary intent-to-treat analyses using imputed data also showed the noninferiority of MBSR compared with escitalopram based on the improvement in CGI-S score. Of patients who started treatment, 10 (8%) dropped out of the escitalopram group and none from the MBSR g …
Secondary intent-to-treat analyses using imputed data also showed the noninferiority of MBSR compared with escitalopram based on the …
Trial of Psilocybin versus Escitalopram for Depression.
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ. Carhart-Harris R, et al. N Engl J Med. 2021 Apr 15;384(15):1402-1411. doi: 10.1056/NEJMoa2032994. N Engl J Med. 2021. PMID: 33852780 Clinical Trial.
RESULTS: A total of 59 patients were enrolled; 30 were assigned to the psilocybin group and 29 to the escitalopram group. The mean scores on the QIDS-SR-16 at baseline were 14.5 in the psilocybin group and 16.4 in the escitalopram group. ...Other secondary outcomes …
RESULTS: A total of 59 patients were enrolled; 30 were assigned to the psilocybin group and 29 to the escitalopram group. The mean sc …
Depression and inflammation: Correlation between changes in inflammatory markers with antidepressant response and long-term prognosis.
Kofod J, Elfving B, Nielsen EH, Mors O, Köhler-Forsberg O. Kofod J, et al. Eur Neuropsychopharmacol. 2022 Jan;54:116-125. doi: 10.1016/j.euroneuro.2021.09.006. Epub 2021 Sep 29. Eur Neuropsychopharmacol. 2022. PMID: 34598835 Free article. Clinical Trial.
We performed secondary analyses among 90 outpatients with moderate-severe depression (71% female, mean age 38 years) treated for 26 weeks with escitalopram or nortriptyline. We measured 27 pro- and anti-inflammatory markers at week 0, 8, 12, and 26 and calculated composite …
We performed secondary analyses among 90 outpatients with moderate-severe depression (71% female, mean age 38 years) treated for 26 weeks wi …
A Cognitive Biotype of Depression and Symptoms, Behavior Measures, Neural Circuits, and Differential Treatment Outcomes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Hack LM, Tozzi L, Zenteno S, Olmsted AM, Hilton R, Jubeir J, Korgaonkar MS, Schatzberg AF, Yesavage JA, O'Hara R, Williams LM. Hack LM, et al. JAMA Netw Open. 2023 Jun 1;6(6):e2318411. doi: 10.1001/jamanetworkopen.2023.18411. JAMA Netw Open. 2023. PMID: 37318808 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of a randomized clinical trial implemented data-driven clustering in findings from the International Study to Predict Optimized Treatment in Depression, a pragmatic biomarker trial in which patients with MDD were randomiz …
DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of a randomized clinical trial implemented data-driven clustering in findings fro …
Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study.
Strawn JR, Mills JA, Schroeder H, Mossman SA, Varney ST, Ramsey LB, Poweleit EA, Desta Z, Cecil K, DelBello MP. Strawn JR, et al. J Clin Psychiatry. 2020 Aug 25;81(5):20m13396. doi: 10.4088/JCP.20m13396. J Clin Psychiatry. 2020. PMID: 32857933 Free PMC article. Clinical Trial.
Vital signs, corrected QT interval, and adverse events were similar in patients who received escitalopram and placebo. CONCLUSIONS: Escitalopram reduces anxiety symptoms, and pharmacogenetics variables influence the trajectory and magnitude of improvement. Variation …
Vital signs, corrected QT interval, and adverse events were similar in patients who received escitalopram and placebo. CONCLUSIONS: …
Effect of Exercise, Escitalopram, or Placebo on Anxiety in Patients With Coronary Heart Disease: The Understanding the Benefits of Exercise and Escitalopram in Anxious Patients With Coronary Heart Disease (UNWIND) Randomized Clinical Trial.
Blumenthal JA, Smith PJ, Jiang W, Hinderliter A, Watkins LL, Hoffman BM, Kraus WE, Liao L, Davidson J, Sherwood A. Blumenthal JA, et al. JAMA Psychiatry. 2021 Nov 1;78(11):1270-1278. doi: 10.1001/jamapsychiatry.2021.2236. JAMA Psychiatry. 2021. PMID: 34406354 Free PMC article. Clinical Trial.
The mean (SD) age was 64.6 (9.6) years, and 37 participants (29%) were women. Participants randomized to the exercise group and escitalopram group reported greater reductions in HADS-A (exercise, -4.0; 95% CI, -4.7 to -3.2; escitalopram, -5.7; 95% CI, -6.4 to -5.0) …
The mean (SD) age was 64.6 (9.6) years, and 37 participants (29%) were women. Participants randomized to the exercise group and escitalop
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.
Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, Duthaler U, Varghese N, Eckert A, Grünblatt E, Liechti ME. Becker AM, et al. Clin Pharmacol Ther. 2022 Apr;111(4):886-895. doi: 10.1002/cpt.2487. Epub 2021 Nov 22. Clin Pharmacol Ther. 2022. PMID: 34743319 Free PMC article. Clinical Trial.
Pretreatment consisted of 10 mg escitalopram daily for 7 days, followed by 20 mg daily for 7 days, including the day of psilocybin administration, or 14 days of placebo pretreatment before psilocybin administration. ...Escitalopram did not alter HTR2A or SCL6A4 gene …
Pretreatment consisted of 10 mg escitalopram daily for 7 days, followed by 20 mg daily for 7 days, including the day of psilocybin ad …
A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder.
Strawn JR, Moldauer L, Hahn RD, Wise A, Bertzos K, Eisenberg B, Greenberg E, Liu C, Gopalkrishnan M, McVoy M, Knutson JA. Strawn JR, et al. J Child Adolesc Psychopharmacol. 2023 Apr;33(3):91-100. doi: 10.1089/cap.2023.0004. J Child Adolesc Psychopharmacol. 2023. PMID: 37074330 Clinical Trial.
Vital signs, weight, laboratory, and electrocardiographic results were consistent with previous pediatric studies of escitalopram. Conclusions: Escitalopram reduced anxiety symptoms and was well tolerated in pediatric patients with GAD. These findings confirm earlie …
Vital signs, weight, laboratory, and electrocardiographic results were consistent with previous pediatric studies of escitalopram. Co …
Citalopram Neuroendocrine Challenge Shows Altered Tryptophan and Kynurenine Metabolism in Migraine.
Gecse K, Édes AE, Nagy T, Demeter AK, Virág D, Király M, Dalmadi Kiss B, Ludányi K, Környei Z, Denes A, Bagdy G, Juhasz G. Gecse K, et al. Cells. 2022 Jul 21;11(14):2258. doi: 10.3390/cells11142258. Cells. 2022. PMID: 35883701 Free PMC article. Clinical Trial.
The involvement of these pathways in migraine has been widely studied, but acute citalopram neuroendocrine challenge on TRP metabolism and cytokine profile has not been investigated yet. ...Our results support a decreased breakdown of TRP via KYN pathway and a failure to m …
The involvement of these pathways in migraine has been widely studied, but acute citalopram neuroendocrine challenge on TRP metabolis …
Comparative effectiveness of antidepressants on geriatric depression: Real-world evidence from a population-based study.
Hsu CW, Tseng WT, Wang LJ, Yang YH, Kao HY, Lin PY. Hsu CW, et al. J Affect Disord. 2022 Jan 1;296:609-615. doi: 10.1016/j.jad.2021.10.009. Epub 2021 Oct 14. J Affect Disord. 2022. PMID: 34655698 Free article. Clinical Trial.
RESULTS: During the study period, a total of 207,946 elderly patients with depression received one of the following 11 antidepressants: sertraline, fluoxetine, paroxetine, escitalopram, citalopram, fluvoxamine, venlafaxine, duloxetine, moclobemide, mirtazapine, and …
RESULTS: During the study period, a total of 207,946 elderly patients with depression received one of the following 11 antidepressants: sert …
1,647 results